gamma-aminobutyric acid has been researched along with Degenerative Diseases, Central Nervous System in 35 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we tested whether LY293558 is effective against soman-induced seizures and neuropathology, when administered 1 h after soman exposure, in rats." | 7.77 | The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. ( Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Qashu, F; Souza, AP, 2011) |
| "LY293558 stopped seizures induced by soman and reduced the total duration of SE, monitored by electroencephalographic recordings within a 24 h-period after exposure." | 5.37 | The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. ( Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Qashu, F; Souza, AP, 2011) |
| " In search of novel neuroprotectants, we showed that butyrate (BUT), a short-chain fatty acid, protects against salsolinol (SALS)-induced toxicity in human neuroblastoma-derived SH-SY5Y cells, which are considered an in-vitro model of PD." | 4.31 | Dihydromyricetin Protects Against Salsolinol-Induced Toxicity in Dopaminergic Cell Line: Implication for Parkinson's Disease. ( Copeland, RL; Csoka, AB; Getachew, B; Manaye, KF; Tizabi, Y, 2023) |
| " Therefore, we tested whether LY293558 is effective against soman-induced seizures and neuropathology, when administered 1 h after soman exposure, in rats." | 3.77 | The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. ( Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Qashu, F; Souza, AP, 2011) |
| "Conversely, cataplexy, one of the key symptoms of narcolepsy, is a striking sudden episode of muscle weakness triggered by emotions during wakefulness, and comparable to REM sleep atonia." | 2.47 | The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. ( Clément, O; Fort, P; Gervasoni, D; Léger, L; Luppi, PH; Peyron, C; Salvert, D; Sapin, E, 2011) |
| "It is hard to define what ratio of insomnia and daytime hypersomnia is caused by the antiparkinsonian treatment, by the somatic and mental-emotional symptoms of the neurodegenerative disease and by the neurodegenerative brain process itself." | 2.44 | [Sleep disorders in Parkinson syndromes]. ( Kovács, GG; Lalit, N; Péter, H; Szucs, A, 2007) |
| "Glaucoma is an age-related neurodegenerative disease of the visual system, affecting both the eye and the brain." | 1.91 | GABA decrease is associated with degraded neural specificity in the visual cortex of glaucoma patients. ( Bang, JW; Chan, KC; Parra, C; Schuman, JS; Wollstein, G; Yu, K, 2023) |
| "l-Theanine is an active constituent of green tea which prevents neuronal loss, mitochondrial failure and improves dopamine, gamma-aminobutyric acid (GABA), serotonin levels and in the central nervous system (CNS) via antioxidant, anti-inflammatory, and neuromodulatory properties." | 1.72 | l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson's disease. ( Gupta, GD; Raj, K; Singh, S, 2022) |
| " Tramadol is safe analgesic but long-term use confirmed to elevate oxidative stress, neuroinflammation, mitochondrial dysfunction, in brain leads to motor deficits." | 1.72 | l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson's disease. ( Gupta, GD; Raj, K; Singh, S, 2022) |
| "Recent data showed that rats induced to Parkinsonism by 6-hydroxydopamine (6-OHDA) administration in the substantia nigra pars compacta (SNpc) showed lower mean arterial pressure (MAP) and heart rate (HR), as reduction in sympathetic modulation." | 1.51 | Glutamate and GABA neurotransmission are increased in paraventricular nucleus of hypothalamus in rats induced to 6-OHDA parkinsonism: Involvement of nNOS. ( Ariza, D; Crestani, CC; Cruz Lucchetti, BF; de Jager, L; Martins, AB; Martins-Pinge, MC; Pinge-Filho, P; Rodrigues, AT; Turossi Amorim, ED; Uchoa, ET, 2019) |
| "Manganese (Mn) is an essential element and it acts as a cofactor for a number of enzymatic reactions, including those involved in amino acid, lipid, protein, and carbohydrate metabolism." | 1.38 | Manganese alters rat brain amino acids levels. ( Almeida, I; Aschner, M; Batoreu, MC; Marreilha dos Santos, AP; Ramos, R; Santos, D; Sidoryk-Wegrzynowicz, M, 2012) |
| "LY293558 stopped seizures induced by soman and reduced the total duration of SE, monitored by electroencephalographic recordings within a 24 h-period after exposure." | 1.37 | The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. ( Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Qashu, F; Souza, AP, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (8.57) | 18.2507 |
| 2000's | 8 (22.86) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 10 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Sood, A | 1 |
| Preeti, K | 1 |
| Fernandes, V | 1 |
| Khatri, DK | 1 |
| Singh, SB | 1 |
| Wang, X | 1 |
| Wu, J | 1 |
| Wang, W | 1 |
| Zhang, Y | 2 |
| He, D | 1 |
| Xiao, B | 1 |
| Zhang, H | 1 |
| Song, A | 1 |
| Xing, Y | 1 |
| Li, B | 1 |
| Perry, A | 1 |
| Hughes, LE | 1 |
| Adams, N | 1 |
| Naessens, M | 1 |
| Murley, AG | 1 |
| Rouse, MA | 1 |
| Street, D | 1 |
| Jones, PS | 1 |
| Cope, TE | 1 |
| Kocagoncu, E | 1 |
| Rowe, JB | 1 |
| Kulick, D | 2 |
| Moon, E | 2 |
| Riffe, RM | 2 |
| Teicher, G | 2 |
| Van Deursen, S | 2 |
| Berson, A | 2 |
| He, W | 2 |
| Aaron, G | 2 |
| Downes, GB | 2 |
| Devoto, S | 2 |
| O'Neil, A | 2 |
| Getachew, B | 1 |
| Csoka, AB | 1 |
| Copeland, RL | 1 |
| Manaye, KF | 1 |
| Tizabi, Y | 1 |
| Mancini, V | 1 |
| Saleh, MG | 1 |
| Delavari, F | 1 |
| Bagautdinova, J | 1 |
| Eliez, S | 1 |
| Bang, JW | 1 |
| Parra, C | 1 |
| Yu, K | 1 |
| Wollstein, G | 1 |
| Schuman, JS | 1 |
| Chan, KC | 1 |
| Jantrapirom, S | 1 |
| Enomoto, Y | 1 |
| Karinchai, J | 1 |
| Yamaguchi, M | 2 |
| Yoshida, H | 1 |
| Fukusaki, E | 1 |
| Shimma, S | 1 |
| Princivalle, AP | 1 |
| Raj, K | 1 |
| Gupta, GD | 1 |
| Singh, S | 1 |
| Wang, J | 1 |
| Chang, X | 1 |
| Qian, J | 1 |
| Jiang, Y | 1 |
| Wang, C | 1 |
| Wang, Y | 2 |
| Feng, C | 1 |
| Xia, P | 1 |
| Wu, D | 1 |
| Zhang, W | 1 |
| Takács, VT | 1 |
| Cserép, C | 1 |
| Schlingloff, D | 1 |
| Pósfai, B | 1 |
| Szőnyi, A | 1 |
| Sos, KE | 1 |
| Környei, Z | 1 |
| Dénes, Á | 1 |
| Gulyás, AI | 1 |
| Freund, TF | 1 |
| Nyiri, G | 1 |
| Turossi Amorim, ED | 1 |
| de Jager, L | 1 |
| Martins, AB | 1 |
| Rodrigues, AT | 1 |
| Cruz Lucchetti, BF | 1 |
| Ariza, D | 1 |
| Pinge-Filho, P | 1 |
| Crestani, CC | 1 |
| Uchoa, ET | 1 |
| Martins-Pinge, MC | 1 |
| Li, Y | 1 |
| Severance, EG | 1 |
| Viscidi, RP | 1 |
| Yolken, RH | 1 |
| Xiao, J | 1 |
| Guerrini, G | 1 |
| Ciciani, G | 1 |
| Sawano, E | 1 |
| Iwatani, K | 1 |
| Tominaga-Yoshino, K | 1 |
| Ogura, A | 1 |
| Tashiro, T | 1 |
| Sargin, D | 1 |
| Hassouna, I | 1 |
| Sperling, S | 1 |
| Sirén, AL | 1 |
| Ehrenreich, H | 1 |
| Earls, LR | 1 |
| Hacker, ML | 1 |
| Watson, JD | 1 |
| Miller, DM | 1 |
| Figueiredo, TH | 1 |
| Qashu, F | 1 |
| Apland, JP | 1 |
| Aroniadou-Anderjaska, V | 1 |
| Souza, AP | 1 |
| Braga, MF | 1 |
| Luppi, PH | 1 |
| Clément, O | 1 |
| Sapin, E | 1 |
| Gervasoni, D | 1 |
| Peyron, C | 1 |
| Léger, L | 1 |
| Salvert, D | 1 |
| Fort, P | 1 |
| Ramamoorthi, K | 1 |
| Lin, Y | 1 |
| Ali, F | 1 |
| Rowley, M | 1 |
| Jayakrishnan, B | 1 |
| Teuber, S | 1 |
| Gershwin, ME | 1 |
| Mackay, IR | 1 |
| Lantos, PM | 1 |
| Santos, D | 1 |
| Batoreu, MC | 1 |
| Almeida, I | 1 |
| Ramos, R | 1 |
| Sidoryk-Wegrzynowicz, M | 1 |
| Aschner, M | 1 |
| Marreilha dos Santos, AP | 1 |
| Moshkin, MP | 1 |
| Akulov, AE | 1 |
| Petrovskiĭ, DV | 1 |
| Saĭk, OV | 1 |
| Petrovskiĭ, ED | 1 |
| Savelov, AA | 1 |
| Koptug, IV | 1 |
| Ikeda, K | 1 |
| Onaka, T | 1 |
| Yamakado, M | 1 |
| Nakai, J | 1 |
| Ishikawa, TO | 1 |
| Taketo, MM | 1 |
| Kawakami, K | 1 |
| Leiva, J | 1 |
| Gaete, P | 1 |
| Palestini, M | 1 |
| Tamano, H | 1 |
| Takeda, A | 1 |
| Doyle, KM | 1 |
| Kirby, BP | 1 |
| Murphy, D | 1 |
| Shaw, GG | 1 |
| Hellstrom, IC | 1 |
| Danik, M | 1 |
| Luheshi, GN | 1 |
| Williams, S | 1 |
| Szucs, A | 1 |
| Kovács, GG | 1 |
| Lalit, N | 1 |
| Péter, H | 1 |
| Rye, DB | 1 |
| Bodis-Wollner, I | 1 |
| Ciesielski-Treska, J | 1 |
| Ulrich, G | 1 |
| Taupenot, L | 1 |
| Chasserot-Golaz, S | 1 |
| Corti, A | 1 |
| Aunis, D | 1 |
| Bader, MF | 1 |
| Picklo, MJ | 1 |
| Olson, SJ | 1 |
| Hayes, JD | 1 |
| Markesbery, WR | 1 |
| Montine, TJ | 1 |
7 reviews available for gamma-aminobutyric acid and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Glia: A major player in glutamate-GABA dysregulation-mediated neurodegeneration.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neurodegenerative Diseases; Neuroglia; Neurons | 2021 |
Benzodiazepine receptor ligands: a patent review (2006-2012).
Topics: Animals; Binding Sites; Cognition Disorders; Drug Design; gamma-Aminobutyric Acid; Humans; Ligands; | 2013 |
The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder.
Topics: Amygdala; Animals; Brain; Brain Mapping; Cataplexy; Emotions; gamma-Aminobutyric Acid; Glutamine; Gl | 2011 |
The contribution of GABAergic dysfunction to neurodevelopmental disorders.
Topics: Animals; Cell Movement; gamma-Aminobutyric Acid; Gene Expression Regulation; Humans; Neurodegenerati | 2011 |
Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies.
Topics: Autoantibodies; Central Nervous System; Diabetes Mellitus, Type 1; Epilepsy; GABAergic Neurons; gamm | 2011 |
[Sleep disorders in Parkinson syndromes].
Topics: Acetylcholine; Antidepressive Agents; Antiparkinson Agents; Diagnosis, Differential; Disorders of Ex | 2007 |
Contributions of the pedunculopontine region to normal and altered REM sleep.
Topics: Acetylcholine; Arousal; Basal Ganglia; Brain Stem; Evoked Potentials, Auditory; gamma-Aminobutyric A | 1997 |
28 other studies available for gamma-aminobutyric acid and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Reprogramming of Rat Fibroblasts into Induced Neurons by Small-Molecule Compounds In Vitro and In Vivo.
Topics: Animals; Cell Differentiation; Cellular Reprogramming; Fibroblasts; GABAergic Neurons; gamma-Aminobu | 2022 |
The neurophysiological effect of NMDA-R antagonism of frontotemporal lobar degeneration is conditional on individual GABA concentration.
Topics: Cross-Over Studies; Double-Blind Method; Frontotemporal Dementia; Frontotemporal Lobar Degeneration; | 2022 |
Amyotrophic Lateral Sclerosis-Associated Persistent Organic Pollutant
Topics: Amyotrophic Lateral Sclerosis; Animals; Chlordan; gamma-Aminobutyric Acid; Humans; Motor Neurons; Ne | 2022 |
Amyotrophic Lateral Sclerosis-Associated Persistent Organic Pollutant
Topics: Amyotrophic Lateral Sclerosis; Animals; Chlordan; gamma-Aminobutyric Acid; Humans; Motor Neurons; Ne | 2022 |
Amyotrophic Lateral Sclerosis-Associated Persistent Organic Pollutant
Topics: Amyotrophic Lateral Sclerosis; Animals; Chlordan; gamma-Aminobutyric Acid; Humans; Motor Neurons; Ne | 2022 |
Amyotrophic Lateral Sclerosis-Associated Persistent Organic Pollutant
Topics: Amyotrophic Lateral Sclerosis; Animals; Chlordan; gamma-Aminobutyric Acid; Humans; Motor Neurons; Ne | 2022 |
Dihydromyricetin Protects Against Salsolinol-Induced Toxicity in Dopaminergic Cell Line: Implication for Parkinson's Disease.
Topics: Cell Line, Tumor; Dopamine; Dopaminergic Neurons; gamma-Aminobutyric Acid; Humans; Neuroblastoma; Ne | 2023 |
Excitatory/Inhibitory Imbalance Underlies Hippocampal Atrophy in Individuals With 22q11.2 Deletion Syndrome With Psychotic Symptoms.
Topics: Atrophy; DiGeorge Syndrome; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Hippocampus; Humans; | 2023 |
GABA decrease is associated with degraded neural specificity in the visual cortex of glaucoma patients.
Topics: Aged; Cognition; gamma-Aminobutyric Acid; Glaucoma; Glutamic Acid; Humans; Neurodegenerative Disease | 2023 |
The depletion of ubiquilin in Drosophila melanogaster disturbs neurochemical regulation to drive activity and behavioral deficits.
Topics: Animals; Courtship; Dopamine; Drosophila melanogaster; Female; gamma-Aminobutyric Acid; Gas Chromato | 2020 |
GABA
Topics: Animals; Central Nervous System; gamma-Aminobutyric Acid; Humans; Neurodegenerative Diseases; Recept | 2022 |
l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson's disease.
Topics: Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; G | 2022 |
[Generation of GABAergic interneuron-specific PGC-1α knockout mice].
Topics: Animals; Female; gamma-Aminobutyric Acid; Humans; Interneurons; Male; Mice; Mice, Knockout; Neurodeg | 2017 |
Co-transmission of acetylcholine and GABA regulates hippocampal states.
Topics: Acetylcholine; Animals; Calcium; Dendrites; Female; gamma-Aminobutyric Acid; Hippocampus; Imaging, T | 2018 |
Glutamate and GABA neurotransmission are increased in paraventricular nucleus of hypothalamus in rats induced to 6-OHDA parkinsonism: Involvement of nNOS.
Topics: Animals; Blood Pressure; Cardiovascular System; gamma-Aminobutyric Acid; Glutamic Acid; Heart Rate; | 2019 |
Persistent
Topics: Animals; Brain; Chemokine CX3CL1; Chronic Disease; Complement Activation; Disease Models, Animal; Fe | 2019 |
Reduction in NPY-positive neurons and dysregulation of excitability in young senescence-accelerated mouse prone 8 (SAMP8) hippocampus precede the onset of cognitive impairment.
Topics: Aging; Animals; Behavior, Animal; Cognition Disorders; Cyclic AMP Response Element-Binding Protein; | 2015 |
Uncoupling of neurodegeneration and gliosis in a murine model of juvenile cortical lesion.
Topics: Animals; Astrocytes; Atrophy; Brain; Brain Injuries; Cold Temperature; Cyclic Nucleotide Phosphodies | 2009 |
Coenzyme Q protects Caenorhabditis elegans GABA neurons from calcium-dependent degeneration.
Topics: Animals; Apoptosis; Apoptotic Protease-Activating Factor 1; Caenorhabditis elegans; Calcium; gamma-A | 2010 |
The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.
Topics: Animals; Chemical Warfare Agents; Electroencephalography; gamma-Aminobutyric Acid; Interneurons; Iso | 2011 |
Chronic Lyme disease: the controversies and the science.
Topics: Amines; Analgesics; Anti-Bacterial Agents; Arthritis, Rheumatoid; Borrelia burgdorferi; Chronic Dise | 2011 |
Manganese alters rat brain amino acids levels.
Topics: Amino Acids; Animals; Brain; Brain Chemistry; Chlorides; Dose-Response Relationship, Drug; Extrapyra | 2012 |
[Magnetic resonance spectroscopy of metabolic changes in mice brain after 2-deoxy-D-glucose injection].
Topics: Animals; Aspartic Acid; Brain; Choline; Deoxyglucose; gamma-Aminobutyric Acid; Glutamic Acid; Glutam | 2012 |
Degeneration of the amygdala/piriform cortex and enhanced fear/anxiety behaviors in sodium pump alpha2 subunit (Atp1a2)-deficient mice.
Topics: Amygdala; Animals; Anxiety; Apoptosis; Astrocytes; Behavior, Animal; Brain Chemistry; Cells, Culture | 2003 |
Copper interaction on the long-term potentiation.
Topics: Animals; Copper; Copper Sulfate; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Pos | 2003 |
Suppressive effect of Saiko-ka-ryukotsu-borei-to, a herbal medicine, on excessive release of glutamate in the hippocampus.
Topics: Animals; Body Weight; Disease Models, Animal; Drugs, Chinese Herbal; Excitatory Amino Acid Antagonis | 2004 |
Effect of L-type calcium channel antagonists on spermine-induced CNS excitation in vivo.
Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Central Nervous System; Convuls | 2005 |
Chronic LPS exposure produces changes in intrinsic membrane properties and a sustained IL-beta-dependent increase in GABAergic inhibition in hippocampal CA1 pyramidal neurons.
Topics: Action Potentials; Animals; Encephalitis; gamma-Aminobutyric Acid; Hippocampus; Interleukin-1; Inter | 2005 |
Vision and neurodegenerative diseases.
Topics: gamma-Aminobutyric Acid; Humans; Neural Pathways; Neurodegenerative Diseases; Nitric Oxide; Retina; | 1997 |
Chromogranin A induces a neurotoxic phenotype in brain microglial cells.
Topics: Animals; Cattle; Cell Survival; Cells, Cultured; Chromogranin A; Chromogranins; Coculture Techniques | 1998 |
Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenerative disease.
Topics: Aged; Alzheimer Disease; Animals; Astrocytes; Brain; Cell Compartmentation; Cerebral Cortex; gamma-A | 2001 |